KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Depreciation & Amortization (CF) (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Depreciation & Amortization (CF) for 17 consecutive years, with $20.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 13.42% year-over-year to $20.4 million, compared with a TTM value of $79.6 million through Dec 2025, down 17.49%, and an annual FY2025 reading of $79.6 million, down 17.49% over the prior year.
  • Depreciation & Amortization (CF) was $20.4 million for Q4 2025 at Biomarin Pharmaceutical, up from $18.5 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $28.0 million in Q1 2021 and bottomed at $18.5 million in Q3 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $24.5 million, with a median of $25.6 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) rose 9.4% in 2023, then dropped 29.85% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $26.0 million in 2021, then fell by 5.51% to $24.6 million in 2022, then rose by 9.4% to $26.9 million in 2023, then dropped by 12.11% to $23.6 million in 2024, then dropped by 13.42% to $20.4 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for BMRN at $20.4 million in Q4 2025, $18.5 million in Q3 2025, and $18.6 million in Q2 2025.